Impfprophylaxe rekurrierender invasiver Erkrankungen mit Meningokokken: Stellungnahme der Kommission für Infektionskrankheiten und Impffragen vom 31. März 2022

Invasive meningococcal diseases are rare but lead to a high morbidity and mortality in the patients. The risk of becoming infected again with a different or the same serotype is significantly increased after an infection has gone through and in the case of certain previous illnesses such as complement defects. The Committee for Infectious Diseases and Vaccinations of the German Academy for Pediatrics and Adolescent Health proposes the following approach for prevention of recurrent invasive meningococcal infections: Children and adolescents without a complete meningococcal vaccination status should be vaccinated with 4CMenB (Bexero®, Trumenba®) and/or vaccinated against serogroups A, C, W and Y (Menveo®, Nimenrix®, MenQuadfi®) immediately after healing of an invasive meningococcal disease according to the specification of the information for healthcare professionals. Prior isolated screening for complement deficiencies is not necessary for the vaccination decision in these patients.